Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
NCT00726180
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class
Stopped
Due to low enrollment
Conditions
Breast Cancer
Interventions
DRUG:
trastuzumab (Herceptin®)
Sponsor
University of Michigan Rogel Cancer Center